ArticleNPJ breast cancer2022

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.

Julie E Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.